目的：研究3%地夸磷索钠滴眼液治疗睑板腺功能障碍相关性干眼的疗效。

方法：选取2020-05/2021-05就诊于杭州市中医院眼科的睑板腺功能障碍相关性干眼患者280例，采用随机数字表法将患者分为治疗组(160例320眼)及对照组(120例240眼)。对照组予养血润目颗粒剂联合0.3%玻璃酸钠滴眼液，治疗组予养血润目颗粒剂联合3%地夸磷索钠滴眼液治疗。两组均连续用药4wk。分别于治疗前、治疗后2、4wk测定以下指标：眼表疾病评分指数(OSDI)评分，基础泪液分泌试验(SⅠt)、眼表综合分析测定泪河高度(TMH)、非侵入性泪膜破裂时间(NITBUT)，睑板腺睑脂分泌通畅度评分，睑板腺管缺失评分，测定泪液中白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平，以评估两种治疗方法的疗效。

结果：治疗组及对照组总体有效率分别为95.6%、81.7%(P<0.05)。治疗2、4wk后两组OSDI评分、NITBUT、睑板腺管缺失评分、睑板腺睑脂分泌通畅度评分、泪液炎症因子TNF-α、IL-6水平较治疗前均有差异(P<0.05)，且治疗组优于对照组； 两组治疗前后SⅠt与TMH组间均无差异(P>0.05)。

结论：3%地夸磷索钠滴眼液可通过延长泪膜的稳态促进睑板腺的正常分泌，还可抑制泪液中炎症因子的释放等作用治疗睑板腺功能障碍相关性干眼。

METHODS: The study involved 280 patients totally with meibomian gland dysfunction-related dry eye in the ophthalmology department, Hangzhou Hospital of Traditional Chinese Medicine from May 2020 to May 2021. Patients were divided into the treatment group(160 cases with 320 eyes)and the control group(120 cases with 240 eyes)according to the randomized number table method. The control group was treated with YangXueRunMu formula combined with 0.3% sodium hyaluronate eye drops, the treatment group was treated with YangXueRunMu formula combined with 3% diquafosol sodium eye drops. Both groups were administered for 4wk. The following indicators were measured before and after treatment at 2 and 4wk, respectively: the ocular surface disease index(OSDI)score, Schirmer I test( SⅠt), comprehensive analysis of tear meniscus height(TMH), non-invasive tear film break-up time(NITBUT), meibomian gland lipid secretion of smooth degree scoring and meibomian gland loss rate score, the determination of interleukin-6(IL-6)in tears and the level of tumor necrosis factor-alpha(TNF-α). The efficacy of these tests results was evaluated among these indicators.

RESULTS: The overall effective rates of the treatment group and the control group were 95.6% and 81.7% respectively(P<0.05). After 2, 4wk of treatment, the ocular surface disease index(OSDI), NITBUT, meibomian gland lipid secretion scoring, meibomian gland loss rate score and the levels of IL-6 and TNF-α in tears of two groups were significantly different than before treatment(P<0.05). and the treatment group was better than the control group; there was no difference between the SⅠt and TMH groups before and after treatment in the two groups(P>0.05).

CONCLUSION: The 3% diquafosol sodium eye drops can promote the normal secretion of meibomian gland by prolonging the homeostasis of the tear membrane, and it can also inhibit the release of inflammatory factors in tears in the treatment of blebomian gland dysfunction-related dry eye.